The SURTAVI study: TAVI for patients with intermediate risk

EuroIntervention 2017;13:e617-e620 published online e-edition August 2017. DOI: 10.4244/EIJV13I5A97

Daniel Jones
Daniel A. Jones1*, MBBS, PhD; Didier Tchétché2, MD; John Forrest3, MD; Farrel Hellig4, BSc, MBBCh, FCP(SA), FSCAI; Alexandra Lansky5, MD; Neil Moat6, MBBS
1. Department of Cardiology, Barts Heart Centre, London, United Kingdom; 2. Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France; 3. Division of Cardiology, Yale School of Medicine, New Haven, CT, USA; 4. Department of Cardiology, S

Introduction to the session: the trial headlines

The aim of this article is to capture the session at EuroPCR 2017 covering the SURTAVI study, communicate the analysis of the trialists, and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.

The SURTAVI study (Safety and Efficacy of the CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement)1 was the focus of the discussion during the dedicated session at EuroPCR 2017 entitled “Will this trial change my ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Interventions for valvular diseaseTAVI
Read next article
Transcatheter Aortic Valve Implantation Versus Re-do Surgery for Failing Surgical Aortic Bioprosthesis: a Multi-Centre Propensity Score Analysis

Latest news